Latest Biotechnology News

Page 10 of 115
Mesoblast has reported a sharp commercial step-up in FY2026, with Ryoncil generating US$115.2 million in net sales and total revenue reaching US$120.3 million. The company has also completed treatment in its 350-patient back-pain trial and refinanced its debt, but remains loss-making and expects to need more capital beyond the next 12 months.
Ada Torres
Ada Torres
12 Oct 2026
Nyrada has lodged a prospectus for approximately 10.74 million free options linked to its recent capital raising, giving eligible CDI holders three options for every four CDIs issued. The options carry a $0.93 exercise price and could generate almost $10 million if fully exercised, although that cash remains contingent on holder participation.
Ada Torres
Ada Torres
12 Oct 2026
Emyria’s FY26 annual report shows a rapidly expanding psychedelic-assisted care network, with revenue up 210% and treatment capacity reaching 18 beds across four states. The gains came alongside a larger loss, $4.6 million in operating cash outflow and an auditor-highlighted material uncertainty over the company’s ability to continue without further funding.
Victor Sage
Victor Sage
9 Oct 2026
Cynata Therapeutics has launched a fully underwritten $913,000 entitlement offer as it reassesses the future of its Cymerus platform after two major trials failed to demonstrate efficacy. The raise provides short-term funding, but the prospectus warns that further capital may be needed and repeats a material uncertainty over going concern.
Ada Torres
Ada Torres
8 Oct 2026
Noxopharm says the FDA has supported its proposed Phase II design and chemical manufacturing strategy for SOF-SKN, its topical treatment candidate for cutaneous lupus erythematosus. The feedback improves regulatory clarity, but the trial remains targeted for the first half of calendar 2028 and is subject to further studies and regulatory requirements.
Ada Torres
Ada Torres
8 Oct 2026
Arovella Therapeutics has released a second clinical batch of its off-the-shelf CAR-iNKT therapy ALA-101, with material expected to support dose escalation and the start of dose expansion in blood cancers. The company is also adding hospital sites ahead of anticipated first-patient dosing in late October.
Ada Torres
Ada Torres
7 Oct 2026
The FDA says positive results from Neurizon’s HEALEY ALS trial could potentially support traditional approval of NUZ-001, with the study possibly serving as the sole registrational trial. The guidance is conditional, but gives the company a clearer regulatory route ahead of topline results expected in late Q2 2027.
Ada Torres
Ada Torres
6 Oct 2026
Neurotech International has moved NTI164 into a registration-enabling Phase III autism trial, but its annual report carries a material going-concern warning. The company says post-year-end debt and equity funding should support the program through topline data, subject to execution and completion.
Ada Torres
Ada Torres
5 Oct 2026
Radiopharm says the FDA has provided a clear framework for the pivotal development of RAD101, its investigational brain metastases imaging agent. The company is preparing for Phase 3 while awaiting formal meeting minutes that could still refine the trial design and regulatory requirements.
Victor Sage
Victor Sage
5 Oct 2026
AdAlta and Shanghai Cell Therapy Group have approved the FDA briefing pack and manufacturing transfer plan for EW-001, bringing the mesothelioma CAR-T therapy closer to an Australian Phase 1 trial. The FDA meeting is scheduled for November, while two Chinese patients remain under follow-up, including a second complete responder.
Ada Torres
Ada Torres
5 Oct 2026
CSL has secured an exclusive agreement to co-develop and co-promote Alentis Therapeutics’ investigational drug lixudebart, committing US$355 million upfront and funding a multi-trial development programme. The antibody remains unapproved, with its commercial potential dependent on results from ongoing and planned clinical studies.
Victor Sage
Victor Sage
5 Oct 2026
Island Pharmaceuticals has begun GMP production of Galidesivir, with the first 5kg batch targeted for an investigational Ebola treatment program in Uganda. A second batch is intended to support a pivotal Marburg animal study under the FDA’s Animal Rule pathway.
Victor Sage
Victor Sage
2 Oct 2026

Browse the archive

Full archive